S
Shinji Matsunaga
Researcher at Fujita Health University
Publications - 52
Citations - 1667
Shinji Matsunaga is an academic researcher from Fujita Health University. The author has contributed to research in topics: Discontinuation & Randomized controlled trial. The author has an hindex of 21, co-authored 52 publications receiving 1219 citations. Previous affiliations of Shinji Matsunaga include University of Mississippi.
Papers
More filters
Journal ArticleDOI
Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis.
TL;DR: Memantine monotherapy improved cognition, behavior, activities of daily living, global function, and stage of dementia and was well-tolerated by AD patients; however, the effect size in terms of efficacy outcomes was small and thus there is limited evidence of clinical benefit.
Journal ArticleDOI
Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.
TL;DR: The meta-analyses suggest the credible efficacy and safety of memantine in treating AD when used alone or in combination with ChEIs.
Journal ArticleDOI
Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
TL;DR: The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.
Journal ArticleDOI
The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder.
Taro Kishi,Reiji Yoshimura,Yasuhisa Fukuo,Tomo Okochi,Shinji Matsunaga,Wakako Umene-Nakano,Jun Nakamura,Alessandro Serretti,Christoph U. Correll,John M. Kane,Nakao Iwata +10 more
TL;DR: It is suggested that rs6295 (C-1019G) and rs878567 in HTR1A are related to the pathophysiology of MDs, with overlap between MDD and BP.
Journal ArticleDOI
Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
TL;DR: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer’s disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated.